Objectives: To evaluate comparatively the results of treatment with interferon, laser and their association in a group of patients with Peyronie's disease.
Methods: We performed an experimental study to evaluate the main results of the treatment of Peyronie's disease with interferon and laser, at Hospital Provincial Universitario "Saturnino Lora Torres" and Hospital General Universitario "Dr. Juan Bruno Zayas Alfonso" in the city of Santiago de Cuba from January 2003 to July 2005. Ninety-six patients were included, divided into three treatment groups: interferon, laser and interferon plus loser. After initial evaluation, treatment was started and continued for 28 weeks, with reevaluation six and 12 months after the end of treatment.
Results: Final results with combined interferon and laser were: symptoms improvement 84.7%, decrease of the size of the fibrous plaque 90.6% and decrease of penile curvature 87.5%.
Conclusions: The combination of both therapies resulted to be more effective than each of them separately, so the recommendation is to incorporate it as another therapeutic alternative in Peyronie's disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4321/s0004-06142008000300008 | DOI Listing |
J Am Chem Soc
January 2025
School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, 637371, Singapore.
Photodynamic therapy (PDT) holds promise as a cancer treatment modality due to its potential for enhanced therapy precision and safety. To enhance deep tissue penetration and minimize tissue adsorption and phototoxicity, developing photosensitizers activated by second near-infrared window (NIR-II) light shows significant potential. However, the efficacy of PDT is often impeded by tumor microenvironment hypoxia, primarily caused by irregular tumor vasculature.
View Article and Find Full Text PDFBr J Dermatol
December 2024
Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Background: The tumour microenvironment significantly influences the clinical response of patients to therapeutic immune checkpoint inhibition (ICI), but a comprehensive understanding of the underlying immune-regulatory proteome is still lacking.
Objectives: To decipher targetable biologic processes that determine tumour-infiltrating lymphocytes (TiLs) as a cellular equivalent of clinical response to ICI.
Methods: We mapped the spatial distribution of proteins in TiL-enriched vs.
J Vis Exp
December 2024
Department of Medical Materials Science & Technology, Institute for Biomedical Engineering, University Hospital Tübingen;
Foreign body reaction (FBR), an immune-mediated complex healing process, plays a crucial role in integrating implants into the body. Macrophages, as the first line of immune system interaction with implant surfaces, play a bidirectional role in modulating the inflammation-regeneration balance. For a deep understanding and the evaluation of the reactions between implant materials and immune responses, reliable in vitro methods and protocols are pivotal.
View Article and Find Full Text PDFJ Infect Dis
December 2024
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background: Hepatitis C virus (HCV) infects nearly one-fourth of people with HIV (PWH). The role of direct-acting antivirals (DAAs) on immune activation in PWH and HCV is poorly understood.
Methods: We quantified plasma HCV RNA and CXCL10 in persons with HCV mono- versus HIV/HCV co-infection receiving Sofosbuvir-Velpatasvir.
J Control Release
December 2024
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, PR China. Electronic address:
Immunotherapy, a pivotal and promising approach for tumor treatment, has demonstrated prominent clinical efficacy. However, its effectiveness is often impeded by insufficient antitumor immune responses attributed to the immunosuppressive tumor microenvironment (TME). The combination of immune activation through the stimulator of interferon genes (STING) pathway and phototherapy holds great potential for surmounting this challenge in advanced tumor immunotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!